Technology Portfolio

Four platforms, four different levels of evidence, one operating model. Aybar Ecotechnologies develops technology to the point where an established operator can take it into manufacturing, registration, and market. We license, co-develop, and take equity. We do not manufacture.

Each entry below states what is proven, what is developed, and what is still being proven. That distinction is the whole point of this page.

01

Energy & Mobility

  • Prototype stage
  • Patent pending
  • NDA-secured negotiations

Gravitational Modulation Platform

Laser-based gravitational field control for levitating transport, low-energy lift systems and aerospace propulsion. Designed for OEM integration, and addressed at the level of the physics rather than the mechanism.

1992Year the underlying theory was published
ModularSurface-integrated, not a discrete engine
3Licensing tracks: aerospace, transport, energy

Technical highlights

  • Modular, surface-integrated architecture
  • Grounded in the EMG Theory of the Photon, published 1992
  • Prototype stage, core mechanism patent-pending

Commercial applications

Aerospace launch assist; levitation-enabled mobility without fixed magnetic infrastructure; gravity-driven power generation; construction, mining and telecom deployment in terrain-inaccessible locations.

Investor & partner opportunities

OEM licensing and development capital to move from prototype to demonstrator. Technical detail beyond the public page is shared under NDA.

Full platform page →
02

Biotech

  • Validated on enzymes
  • Industrial pilot pending

Proprietary Protein Purification Protocol

Purification is 50% to 80% of the production cost of a therapeutic protein. The Aybar Protocol compresses it into a single chromatography step, on the FPLC and HPLC infrastructure producers already own.

1 stepReplaces a 5-step sequence
23×Purification in that single step
4–6 daysTo process 60 lb of yeast, against 6 months
80+Affinity column reuse cycles

Technical highlights

  • 80–90% reduction in buffer use; 8–10× lower dilution
  • Elution in 1–3 column void volumes, against 30
  • Column regeneration in 3 hours, against several days
  • Semi-continuous and programmable; no new capital equipment

Commercial applications

Functional food ingredients, nutraceuticals, therapeutic proteins and plant-based proteins. Addressable market above $700B across those segments; the purification consumables and services market alone is $19B.

Investor & partner opportunities

Volume-based licensing, purification-as-a-service, and joint ventures with ingredient firms. We will run the protocol on one of your protein products at no cost, given starting material and facility access.

Full platform page →
03

Health

  • Dental: clinically validated
  • Granted: Japan, Mexico
  • Pending: United States
  • Medical & veterinary: in development

Universal Bactericide Platform

Lysozyme, a chelation system and a pH-stabilized formulation, active against gram-positive and gram-negative bacteria through a mechanism that does not apply the selective pressure antibiotics do, and therefore does not breed resistance.

n=70Human subjects, dental clinical study
0Bleeding sites recorded at 14 days
0Adverse events attributable to the formulation
2040Mexican patent in force until

Evidence by application

  • Dental: clinically validated in humans, under bioethical approval
  • Medical and veterinary: developed and investigated, not represented as clinically validated
  • Respiratory: largest opportunity, least developed; seeking clinical partners

Intellectual property

One family from a single May 2020 international filing. JP 7768769 granted 4 November 2025. MX 433331 granted 23 March 2026, in force to 28 May 2040. US 2022/0362354 A1 published, application pending.

Investor & partner opportunities

Licensing and co-development with partners able to develop, register, manufacture and commercialize. Phase 1 market entry is an oral chewable under DSHEA. Full dossier under NDA.

Full platform page →
04

Biofuel

  • Laboratory scale proven
  • Demonstration plant sought

CS-Ethanol Technology

Cellulosic ethanol has never failed for lack of feedstock. It has failed on process economics. This route hydrolyses the sugar polymers enzymatically, recovers the lignin as fuel, and leaves practically no inhibitory by-products behind.

>95%Cellulose conversion from corncob
<4 hHydrolysis residence time, against days
138Gallons of ethanol per dry ton of corncob
696KWH electric potential from bagasse lignin

Technical highlights

  • About 99% hemicellulose conversion on both feedstocks
  • Lignin recovered as fuel at roughly 22,000 Btu/kg
  • Solvent and cellulolytic enzymes recovered and recycled
  • Low energy consumption and low equipment investment

Commercial applications

Sugar mills, corn and rice processing, and any operation where lignocellulosic residue already accumulates in volume at a fixed location. The feedstock is agricultural waste, so it does not compete with food production for land.

Investor & partner opportunities

We are seeking a partner to install a demonstration plant and complete the development process. Laboratory results need confirmation at scale, and that gap is exactly where cellulosic ethanol projects have historically failed.

Full platform page →

Licensing & partnerships

Work with us on what comes next

Aybar Ecotechnologies works through licensing, joint ventures, and equity structures. Request the investor brief for a specific platform, or schedule a technical demonstration with our research team.